Company Filing History:
5 out of 1,982 
3 out of 66 
Years Active: 1998-2011
Title: **Yves A DeClerck: Innovator in Metalloproteinase Inhibition**
Introduction
Yves A DeClerck, based in Los Angeles, California, is a distinguished inventor recognized for his significant contributions to the field of pharmaceutical sciences. With a total of five patents to his name, DeClerck has focused his research on the mechanisms of metalloproteinases, paving the way for potential treatments for disorders associated with these enzymes.
Latest Patents
DeClerck's latest innovations include groundbreaking patents related to metalloproteinase inhibitors. His first patent describes a novel metalloproteinase inhibitor, along with its analogs, polynucleotides encoding the same, and various methods of production. This invention presents pharmaceutical compositions and methods to treat disorders caused by excessive metalloproteinase activity. Similarly, another patent outlines methods for detecting metalloproteinase inhibitors, emphasizing the therapeutic potential of these compounds.
Career Highlights
Throughout his career, Yves A DeClerck has been associated with reputable organizations such as Amgen Inc. and the Children's Hospital of Los Angeles. His work at these institutions has allowed him to refine his expertise in drug development and contribute significantly to the advancement of medical science.
Collaborations
In his professional journey, DeClerck has collaborated with notable colleagues, including Keith E Langley and Thomas Charles Boone. These collaborations have further enriched his research, fostering an environment of innovation and discovery in the field of metalloproteinase studies.
Conclusion
Yves A DeClerck stands out as a prominent figure in the realm of pharmaceutical inventions. His dedication to understanding and inhibiting metalloproteinases positions him as a key contributor to potential breakthroughs in medical treatments. With a robust portfolio of patents and collaborative efforts, DeClerck's work continues to influence the future of therapeutics in healthcare.